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Anti-tuberculosis drugs frequently result in cutaneous adverse reactions, including pruritus, maculopapular exanthems, and urticaria. However, anti-
tuberculosis drug-associated cutaneous leukocytoclastic vasculitis (CLV) has been rarely reported. We describe a case of CLV induced by rifampin 
and pyrazinamide. A 38-year-old male had been diagnosed with pulmonary tuberculosis two months ago and then he started standard anti-tubercu-
losis therapy with isoniazid, rifampin, ethambutol, and pyrazinamide. Purpuric lesions developed in the extremities after 1.5 months of anti-tubercu-
losis medication; the lesions progressively spread over the entire body. Histopathology of the purpuric skin lesion was consistent with leukocytoclas-
tic vasculitis. The skin lesion improved after cessation of anti-tuberculosis medications and treatment with oral corticosteroids and antihistamines. 
Anti-tuberculosis drugs were rechallenged one at a time over 3 days. Purpura recurred on the right forearm and forehead after taking 300 mg of ri-
fampin. The skin lesion disappeared after taking oral prednisolone. Finally, 1,500 mg of pyrazinamide was readministrated, and then purpuric lesions 
recurred on both forearms. This report describes a case of leukocytoclastic vasculitis secondary to rifampin and pyrazinamide therapy.
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INTRODUCTION
Cutaneous leukocytoclastic vasculitis (CLV) is confined to 
capillaries and post-capillary venules of the superficial plexus.
1 
The main clinical lesions of CLV are purpuric papules, although 
other clinical findings secondary to ischemia, including ulcer-
ation, may occur.
2 Causes of CLV include drugs, infection, con-
nective tissue disease, and malignancy. An estimated 20-30% of 
all vasculitis cases are attributed to drug administration.
3 CLV 
has rarely been reported in association with tuberculosis or an-
ti-tuberculosis medications.
4-6 A case of rifampin-induced He-
noch-Schönlein purpura was reported in Korea;
7 however, the 
case presented here is, to our knowledge, the first case of CLV 
following treatment with rifampin and pyrazinamide.
CASE REPORT
A 38-year-old male presented to our hospital emergency 
room with palpable purpura of the trunk and extremities. He 
had been diagnosed with pulmonary tuberculosis 2 months 
earlier. The patient had a history of idiopathic cardiomyopathy 
and diabetes mellitus; treatment included daily digoxin 0.125 
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mg, furosemide 40 mg, candesartan cilexetil 8 mg, glimepiride 
2 mg, metformin 500 mg, and voglibose 0.6 mg. When the diag-
nosis of tuberculosis was confirmed by sputum acid fast bacilli 
(AFB) staining, standard anti-tuberculosis therapy was initiated 
with isoniazid (Myambutol
®, Yuhan Corp., Suwon, Korea), ri-
fampin (Rifodex
®, Chongkundang, Suwon, Korea), ethambutol 
(Myambutol
®, Yuhan Corp.), and pyrazinamide (Pyrazinamid
®, 
Yuhan Corp.). After 1.5 months of anti-tuberculosis therapy, a 
purpuric, non-blanching rash appeared on the lower and up-
per extremities. The skin lesions spread progressively over the 
entire body, and several lesions coalesced, resulting in blisters 
and ulcers (Fig. 1). The patient had no history of atopy or drug 
allergy.
Chest radiographs revealed a speculated nodule and multiple 
satellite nodules in the left upper lung field; this was suggestive 
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of pulmonary tuberculosis, with no significant changes from 
the previous radiographic study. However, the sputum AFB 
smear had become negative. Blood tests showed the following: 
leukocytes, 7,500×10
3/μL (neutrophils, 76.4%; lymphocytes, 
14.0%; monocytes, 7.6%; eosinophils, 0.8%); hematocrit, 37.8%; 
hemoglobin, 12.4 g/dL; platelet count, 227,000×10
3/μL; serum 
creatinine, 1.1 mg/dL; aspartate aminotransferase, 25 U/L; ala-
nine aminotransferase, 18 U/L; HBsAg negative, anti-HBs anti-
body negative, anti-HCV antibody negative, syphilis serology 
negative, and anti-HIV negative. Rheumatoid factor, ANA, and 
ANCA tests were also negative. Prothrombin time and activated 
partial thromboplastin time were normal. The fibrinogen deg-
radation product and D-dimer were increased to 5.0 µg/mL 
(reference range, 0.0-4.0 µg/mL) and 1,225 ng/mL (0-200 ng/
mL), respectively. The serum levels of IgG, IgA, IgM, and com-
plement, and the erythrocyte sedimentation rate were within 
normal limits. The level of C-reactive protein was slightly elevat-
ed at 1.12 mg/dL (0.02-0.80 mg/dL). Urinalysis provided no evi-
dence of proteinuria or hematuria. Skin biopsy of the cutane-
ous purpuric lesions revealed leukocytoclastic vasculitis (Fig. 2).
The anti-tuberculosis medications were stopped after admis-
sion due to a clinical suspicion of a drug-induced adverse cuta-
neous reaction. Levofloxacin (500 mg) was administered as a 
second-line anti-tuberculosis medication during hospitaliza-
tion. The patient was treated with prednisolone (20 mg) for 3 
days; the dose was reduced on progressive improvement of the 
vasculitis lesions. We performed rechallenge with each anti-tu-
berculosis drug after 10 days, as described in Table 1. No ad-
verse reactions were observed after ethambutol (400 mg) and 
isoniazid (300 mg) were reintroduced. After rifampin (150 mg) 
therapy, no specific cutaneous findings were noted, but purpu-
ra appeared on the right forearm with increasing the dosage to 
Fig. 1.  Palpable purpura and ulcerations developed on the upper and lower extremities of a patient undergoing rifampin and pyrazinamide therapy.
Fig. 2.  Biopsy of skin lesions: dermal small vessels show fibrinoid change, perivascular neutrophilic and eosinophilic infiltrate and nuclear debris. This is consistent 
with the characteristic feature of leukocytoclastic vasculitis.Allergy Asthma Immunol Res. 2010 January;2(1):55-58.  doi: 10.4168/aair.2010.2.1.55
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300 mg. The skin lesion resolved after 3 days of prednisolone 
treatment (20 mg). Pyrazinamide treatment (1,500 mg) was ini-
tiated, and new purpuric lesions were seen on both forearms 3 
days post-administration. Consequently, he was treated with 
isoniazid, ethambutol, levofloxacin, and kanamycin without 
the recurrence of purpura.
DISCUSSION
Cutaneous adverse reactions to anti-tuberculosis drugs have 
been reported in up to 5% of treated patients.
8 Common cuta-
neous reactions include pruritus, skin eruptions, maculopapu-
lar exanthems, urticaria, pustules, fixed reactions, and erythe-
ma nodosum; these reactions can be controlled with the ad-
ministration of antihistamines.
8,9
Cutaneous leukocytoclastic vasculitis is a rare complication of 
anti-tuberculosis medications. The combination of vasculitis 
and tuberculosis was first described in 1967.
10 There are two 
general types of pulmonary tuberculosis-related vasculitis: leu-
kocytoclastic vasculitis (a manifestation of pulmonary tubercu-
losis) and anti-tuberculosis medication-associated vasculitis 
(particularly with rifampin therapy).
4
Direct vasculitic lesions result from the deposition of bacilli. 
By contrast, microorganisms are not identified in hypersensi-
tivity vasculitis, which may result from the deposition of im-
mune complexes formed by antibodies against Mycobacterium 
tuberculosis proteins. The existence of such circulating immune 
complexes has been demonstrated in 56% of patients with ac-
tive tuberculosis.
11 Tuberculids may be a hypersensitivity reac-
tion to M. tuberculosis after it spreads hematogenously from a 
focus of infection elsewhere. Histologically, a tuberculid is com-
posed of granulomatous inflammation, variable necrosis, and 
variable vasculitis. The lesions respond dramatically to antitu-
berculosis therapy.
12 The possibility of a tuberculosis-associat-
ed direct lesion or hypersensitivity vasculitis as the cause of CLV 
in this patient was unlikely, as the vasculitic lesions developed 
after 1.5 months of anti-tuberculosis medication. Furthermore, 
the sputum AFB staining and M. tuberculosis cultures were neg-
ative at the time the vasculitis developed.
Several studies have described a relationship between ri-
fampin use and vasculitis onset.
5,6 In contrast to tuberculosis-
related vasculitis, the skin lesions of rifampin-induced vasculi-
tis typically improve upon withdrawal of the medication. Previ-
ous studies have suggested that anti-rifampin antibodies con-
tribute to the vasculitis pathogenesis.
13 Although there has been 
no report of an association between pyrazinamide and vasculi-
tis, the incidence of pyrazinamide-induced hepatotoxicity and 
other cutaneous adverse reactions is significantly higher than 
the incidence related to other anti-tuberculosis drugs in Korea 
and other Western countries.
14-16 The development of urticaria 
or exanthem within 1 to 2 hours of an initial pyrazinamide dose 
has been reported,
17 and pyrazinamide-induced erythema 
multiforme was confirmed by rechallenge in another study.
18 
Those studies revealed the causal relationship between the 
drug and the skin lesions, but no mechanism was documented. 
Similarly, our patient had a severe cutaneous adverse reaction 
that improved when the causative drug was withdrawn and re-
curred after rechallenge. Moreover, there was no cause of the 
vasculitis except pyrazinamide, and the pathological findings 
were compatible with leukocytoclastic vasculitis, although the 
pathogenic mechanism remains unclear.
Risk factors for severe adverse anti-tuberculosis drug reac-
tions include older age, female gender, diabetes mellitus, previ-
ous anti-tuberculosis therapy, and a history of hepatitis. Age 
older than 60 years and a birthplace in Asia are significantly as-
sociated with rifampin and pyrazinamide intolerance.
14 Our pa-
tient had two risk factors: he was Asian and had diabetes melli-
tus.
We described a case of rifampin- and pyrazinamide-induced 
CLV confirmed by histology and drug rechallenge. Although 
rarely seen, rifampin and pyrazinamide should be considered 
potential causes of drug-induced CLV.
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Table 1.  Time course, dosage and symptom in the rechallenge of anti-tuberculosis medication
Medication Hospital day (HD) Dosage Symptom
Ethambutol
(Myambutol
®, Yuhan)
HD 10
HD 11
400 mg 2 times a day
800 mg once a day
None
None
Isoniazid
(Yuhan-zid
®, Yuhan)
HD 11
HD 12
100 mg 3 times a day
300 mg once a day
None
None
Rifampin
(Rifodex
®, Chongkundang)
HD 14
HD 15
150 mg once a day
300 mg 2 times a day
None
Purpura
Pyrazinamide
(Pyrazinamid
®, Yuhan)
HD 20
HD 21
HD 22
500 mg 3 times a day
1,500 mg once a day
1,500 mg once a day
None
None
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